Olaparix (Olaparib) 150 MG – 120 Tablets


Olaparib, a PARP inhibitor, is indicated for:
Ovarian Cancer: First-line maintenance treatment for advanced BRCA-mutated cases. Maintenance treatment for recurrent cases after platinum-based chemotherapy. Treatment of advanced BRCA-mutated ovarian cancer after three or more prior lines of chemotherapy.
Breast Cancer: Treatment for HER2-negative metastatic breast cancer with deleterious BRCA mutations, post-chemotherapy in neoadjuvant, adjuvant, or metastatic settings.

Whatsapp +8801922101029